Good Lifestyle

Last month, Covid Numbers Platora and then recently, they started climbing into aDangerous trajectory This suggests that we are far from getting out of the woods. Experts say that the rise of US caisses is probably due to two things: relaxed restrictions and the presence of new more contagious variants in the United States, Brazil and South Africa. These strains add a new unpredictable element to the pandemic, that many health professionals warn could counteract our efforts to achieve the immunity of the flock.

Yet there are many reasons to be carefully optimistic about the future of the pandemic, vaccines being in chief among them. With threeVery effective shots On the market, we now have a way to repel these new variants of Covid slowly for their spread. And while one of the current vaccinesmay Be effective against emerging variants, only one company has formally evaluated their own product and has judged it effective against these new threats. Read to find out what vaccine has been put to the test and for more vaccination news, discoverThe Pfizer vaccine protects you at least this long study discovery.

A team of Pfizer researchers and the Medical Directorate of the University of Texas has responded to the question of whether vaccines developed to combat older COVID variants would protect against new strains. Finally publish their results in theNew England Journal of MedicineIn March, they put in place a laboratory test to test antibodies in samples of sera of 15 volunteers who had received both vaccine doses. In this small sample, they discovered that the vaccine generatedA "substantial" antibody response Laboratory engineering versions of virus variants.

"Taken together, these results indicate that this vaccine is likely to beeffective against the variants studied, although it is precisely how effective they are in the real world will require data on the real effects of the vaccine in the population, not only in laboratory studies such as this one, "reportsBBC Science Focus Magazine. Other studies are likely to examine other aspects of the immune response, including the immunity of the T cell (cell), they explain. And for more COVID news, delivered directly to your inbox,Sign up for our daily newsletter.

While the Pfizer vaccine seemed to protect against all new variants, the study revealed that it has done so as to vary from degrees depending on the type of variant. The team discovered that the shot was the most protective against the original strain and variant B.1.1.7 first detected in the U.K., While a slightly lower response against theP.1 Variant of Brazil. The vaccine against Pfizer was considered less against variant B.1.351 first identified in South Africa.

"Rassable, while the levels were lower for [Brazilian and South African] variants, they were still substantial and likely to indicate that the vaccine will be effective"Peter English, MD, a consultant in control of communicable diseases, saysScientific focus. And for more information on the performance of the Pfizer shot, checkThe vaccine against Pfizer is 100% effective for people this age, said.

As Reuters report, Pfizer has announced a phase 3 update to its test data on April 1: their two-dose vaccine is now considered.91% effective, a slightly lower overall efficiency rate than previously announced.

Additional data came from 12,000 people inoculated for at least six months, as well as "a small subset of volunteer study in South Africa", where Variant B.1.351 is widespread. Although in facial value, this may seem to advance the results of the initial trial of 44,000 volunteers, this new confirms that the vaccine against Pfizer offers powerful protection in an increasingly complicated pandemic landscape.

And for more information on how Pfizer affects patients, checkThe effect on one side that is much more common with Pfizer, data data.

Although the current Pfizer vaccine seems to provide significant protection against COVID variants, the company recently reiterated that they still anticipate a need for booster shots and an improved vaccine.

On February 25, the pharmaceutical company announced that it would start assessing reminder shots in relation to new variants. "We want to be prepared for different scenarios"Ugur sahin, CEO and co-founder of Biontech, who co-created the vaccine against Pfizer, said in the announcement. "Therefore, we will evaluate a second booster In the current regime, as well as preparing a quick rapid adaptation of the vaccine to handle new variants that may escape the current version of our mRNA-based vaccine. "And for more information on the effectiveness of Pfizer vaccine, check The vaccine against Pfizer can be less effective if you have this common condition .